Biomarkers for early diagnosis of Alzheimer disease:: 'ALZheimer ASsociated gene' -: a new blood biomarker?

被引:46
作者
Jellinger, Kurt A. [1 ]
Janetzky, Bernd [2 ]
Attems, Johannes [3 ]
Kienzl, Elisabeth [4 ]
机构
[1] Inst Clin Neurobiol, A-1170 Vienna, Austria
[2] Tech Univ, Neurol Clin, Dresden, Germany
[3] OWS Hosp, Dept Pathol, Vienna, Austria
[4] Vienna Univ Technol, TU Biomed Neurosci, Vienna, Austria
关键词
Alzheimer disease; dementia; ALZAS protein; serum ELISA test; biomarker;
D O I
10.1111/j.1582-4934.2008.00313.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Simple, non-invasive tests for an early detection of degenerative dementia by use of biomarkers are urgently required. However, up to the present, no validated extracerebral diagnostic markers (plasma/serum, platelets, urine, connective tissue) for the early diagnosis of Alzheimer disease (AD) are available. In disease stages with evident cognitive disturbances, the clinical diagnosis of probable AD is made with around 90% accuracy using modern clinical, neuropsychological and imaging methods. Diagnostic sensitivity and specificity even in early disease stages are improved by CSF markers, in particular combined tau and amyloid beta peptides (A beta) and plasma markers (e.g. A beta-42/A beta-40 ratio). Recently, a novel gene/protein - ALZAS (ALZheimer ASsociated protein) - with a 79 amino acid sequence, containing the amyloid beta-42 fragment (A beta-42), the amyloid precursor protein (APP) transmembrane signal and a 12 amino acid C-terminal, not present in any other known APP alleles, has been discovered on chromosome 21 within the APP region. Reverse transcriptase-PCR revealed the expression of the transcript of this protein in the cortex and hippocampal regions as well as in lymphocytes of human AD patients. The expression of ALZAS is mirrored by a specific autoimmune response in AD patients, directed against the ct-12 end of the ALZAS-peptide but not against the A beta-sequence. ELISA studies of plasma dectected highest titres of ALZAS in patients with mild cognitive impairment (presymptomatic AD), but only moderately increased titres in autopsy-confirmed AD, whereas low or undetectable ct-12 titres were found in cognitively intact age-matched subjects and young controls. The antigen, ALZAS protein, was detected in plasma in later clinical stages of AD. It is suggested that ALZAS represents an indicator in a dynamic equilibrium between both peripheral and brain degenerative changes in AD and may become a useful 'non-invasive' diagnostic marker via a simple blood test.
引用
收藏
页码:1094 / 1117
页数:24
相关论文
共 302 条
  • [21] BERGMANN J, 2008, 10 INT HONG KONG SPR
  • [22] Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias
    Bibl, M.
    Mollenhauer, B.
    Lewczuk, P.
    Esselmann, H.
    Wolf, S.
    Trenkwalder, C.
    Otto, M.
    Stiens, G.
    Ruether, E.
    Kornhuber, J.
    Wiltfang, J.
    [J]. MOLECULAR PSYCHIATRY, 2007, 12 (07) : 671 - 680
  • [23] CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
    Bibl, M
    Mollenhauer, B
    Esselmann, H
    Lewczuk, P
    Klafki, HW
    Sparbier, K
    Smirnov, A
    Cepek, L
    Trenkwalder, C
    Rüther, E
    Kornhuber, J
    Otto, M
    Wiltfang, J
    [J]. BRAIN, 2006, 129 : 1177 - 1187
  • [24] Cerebrospinal fluid neurochemical phenotypes in vascular dementias: Original data and mini-review
    Bibl, Mirko
    Mollenhauer, Brit
    Esselmann, Hermann
    Schneider, Michael
    Lewczuk, Piotr
    Welge, Volker
    Gross, Martin
    Falkai, Peter
    Kornhuber, Johannes
    Wiltfang, Jens
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2008, 25 (03) : 256 - 265
  • [25] Blood-based neurochemical diagnosis of vascular dementia: A pilot study
    Bibl, Mirko
    Esselmann, Hermann
    Mollenhauer, Brit
    Weniger, Godehard
    Welge, Volker
    Liess, Michael
    Lewczuk, Piotr
    Otto, Markus
    Schulz, Joerg B.
    Trenkwalder, Claudia
    Kornhuber, Johannes
    Wiltfang, Jens
    [J]. JOURNAL OF NEUROCHEMISTRY, 2007, 103 (02) : 467 - 474
  • [26] Plasma amyloid β protein 42 in non-demented persons aged 75 years:: Effects of concomitant medication and medial temporal lobe atrophy
    Blasko, I
    Kemmler, G
    Krampla, W
    Jungwirth, S
    Wichart, I
    Jellinger, K
    Tragl, KH
    Fischer, P
    [J]. NEUROBIOLOGY OF AGING, 2005, 26 (08) : 1135 - 1143
  • [27] Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine
    Blasko, Imrich
    Jellinger, Kurt
    Kemmler, Georg
    Krampla, Wolfgang
    Jungwirth, Susanne
    Wichart, Ildigo
    Tragl, Karl Heinz
    Fischer, Peter
    [J]. NEUROBIOLOGY OF AGING, 2008, 29 (01) : 1 - 11
  • [28] CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment
    Blennow, K
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2005, 5 (05) : 661 - 672
  • [29] Longitudinal stability of CSF biomarkers in Alzheimer's disease
    Blennow, Kaj
    Zetterberg, Henrik
    Minthon, Lennart
    Lannfelt, Lars
    Strid, Stig
    Annas, Peter
    Basun, Hans
    Andreasen, Niels
    [J]. NEUROSCIENCE LETTERS, 2007, 419 (01) : 18 - 22
  • [30] Alzheimer's disease
    Blennow, Kaj
    de Leon, Mony J.
    Zetterberg, Henrik
    [J]. LANCET, 2006, 368 (9533) : 387 - 403